Ascendis Pharma Reports Full Year 2017 Financial Results

Pharmaceutical Investing

Ascendis Pharma (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the full year ended December 31, 2017. As quoted in the press release: “We are excited by the progress of our rare disease endocrinology pipeline and the potential to …

As quoted in the press release:

“We are excited by the progress of our rare disease endocrinology pipeline and the potential to bring patients differentiated treatments for unmet medical needs. We anticipate data across all three of our clinical programs in the next twelve months, including full data from our ongoing phase 1 trial of TransCon PTH, top-line data from our planned TransCon CNP phase 1 trial, and top-line data from our phase 3 heiGHt Trial for TransCon Growth Hormone,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “The value of our TransCon technology platform is increasing as we move into multiple clinical programs, and we continue to see the broad applicability of our technology.”

Click here to read the full press release.

disease financial results patients phase 1 trial pipeline rare disease rare diseases Pharmaceutical Investing